Molecular and Cell Biology of Human Gene Therapeutics

1. Front Matter

   Pages i-xv

   PDF

2. Retroviral vectors

   • Ariberto Fassati, Matthew G. Dunckley, George Dickson

   Pages 1-19

3. Adenoviral vectors

   • Martin G. Lee, Eric J. Kremer, Michel Perricaudet

   Pages 20-32

4. Herpes simplex virus vectors

   • Joseph Glorioso, Mary Ann Bender, David Fink, Neal Deluca

   Pages 33-63

5. Liposome-mediated gene transfer

   • Itaru Yanagihara, Yasufumi Kaneda, Koji Inui, Shintaro Okada

   Pages 64-82

6. Intramuscular injection of plasmid DNA

   • Dominic J. Wells

   Pages 83-103

7. Yeast artificial chromosome vectors

   • Stewart A. Fabb, Jiannis Ragoussis

   Pages 104-124

8. Gene transfer and cancer chemotherapy

   • Donald W. Moorman, Kenneth W. Culver

   Pages 125-139

9. Vaccine immunotherapy for cancer

   • John Bridgewater, Mary Collins

   Pages 140-156

10. Inherited immunodeficiencies

    • Christine Kinnon

    Pages 157-174

11. Anti-viral strategies

    • Marinee K. L. Chuah, Thierry Vandendriessche, Richard A. Morgan

    Pages 175-194

12. AIDS and HIV infection

    • Clay Smith, Bruce A. Sullenger

    Pages 195-236

13. Cystic fibrosis and lung diseases

    • Samuel C. Wadsworth, Alan E. Smith

    Pages 237-251

14. Arthritis

    • Christopher H. Evans, Paul D. Robbins

    Pages 252-260

15. Duchenne muscular dystrophy

    • George Dickson, Susan C. Brown

    Pages 261-280

16. Cardiovascular disease

    • Howard Prentice, Keith A. Webster

    Pages 281-300

17. Degenerative and inherited neurological disorders

    • Pedro R. Lowenstein

    Pages 301-349

18. Mucopolysaccharidosis

    • Olivier Danos, Jean-Michel Heard

    Pages 350-367

19. DNA-based immunization

    • Heather L. Davis, Robert G. Whalen

    Pages 368-387

20. Back Matter

    Pages 388-403

    PDF

advanced metastatic disease of solid tumors, dictates that each tumor mass, indeed each individual metastasis, will have a unique antigen and cytokine environment and hence unique response to immune modu­ lation. A differential response to immunotherapy is thus inevitable. 4. Many of the human trials described are not randomized and report survival or response against historical controls. Most tumors described are immunogenic human tumors: renal cell cancer and melanoma are most common. In order to avoid the well-described inter-patient vari­ ation and rare incidence of spontaneous response among patient samples as well as selection bias and changes in practice over time, randomized trials are required. 5. Immunological treatment is unlike conventional chemotherapy in its endpoint. Most chemotherapeutic regimes require a complete response or a good partial response for cure or good palliation. There are now many cases where immunotherapy has provided long-term palliation without massive tumor reduction. Immunity may be stimulated to a degree which holds tumorigenicity in check and most importantly, pro­ vides good palliation for the patient in a manner that differs essentially from chemotherapy.

• Chromosom
• DNA
• gene therapy
• gene transfer
• genes

• Department of Biochemistry, Royal Holloway, University of London, Egham, Surrey, UK

  George Dickson

Policies and ethics